Cantor Fitzgerald Reiterates Overweight on Mainz Biomed, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Mainz Biomed (NASDAQ:MYNZ) and maintained a $9 price target.
September 14, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on Mainz Biomed and maintained a $9 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Mainz Biomed. The maintained price target of $9 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100